Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta-cell area and function in Zucker diabetic fatty rats

British Journal of Pharmacology

Volumn 167, Issue 1, 2012, Pages 151-163

  Feigh, M ^a   Andreassen, K V ^a   Neutzsky Wulff, A V ^a   Petersen, S T ^a   Hansen, C ^a   Bay Jensen, A C ^a   Henriksen, J E ^b   Beck Nielsen, H ^b   Christiansen, C ^a   Henriksen, K ^a   Karsdal, M A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

anti diabetic agent; beta cells; hyperglycaemia; salmon calcitonin; type 2 diabetes

Indexed keywords

CALCITONIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; RECOMBINANT CALCITONIN; RECOMBINANT HORMONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CELL FUNCTION; CELL STRUCTURE; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HYPERGLUCAGONEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN SYNTHESIS; RAT; SALMON; ZUCKER DIABETIC FATTY RAT;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; CALCITONIN; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MALE; RATS; RATS, ZUCKER;

EID: 84864696462     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01979.x     Document Type: Article

References (51)

1. Amiel SA, Dixon T, Mann R, Jameson K, (2008). Hypoglycaemia in Type 2 diabetes. Diabet Med 25: 245-254.
2. Bergman RN, Finegood DT, Kahn SE, (2002). The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 32 (Suppl 3): 35-45.
3. Chan JL, Roth JD, Weyer C, (2009). It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development. J Investig Med 57: 777-783.
4. Chelikani PK, Haver AC, Reidelberger RD, (2007). Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats. Am J Physiol Regul Integr Comp Physiol 293: R1798-R1808.
5. Chen J, Pasricha PJ, Yin J, Lin L, Chen JD, (2010). Hepatic electrical stimulation reduces blood glucose in diabetic rats. Neurogastroenterol Motil 22: 1109-e286.
6. Dunning BE, Gerich JE, (2007). The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 28: 253-283.
7. Edelman S, Maier H, Wilhelm K, (2008). Pramlintide in the treatment of diabetes mellitus. BioDrugs 22: 375-386.
8. Eiden S, Daniel C, Steinbrueck A, Schmidt I, Simon E, (2002). Salmon calcitonin-a potent inhibitor of food intake in states of impaired leptin signalling in laboratory rodents. J Physiol 541: 1041-1048.
9. Etgen GJ, Oldham BA, (2000). Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. Metabolism 49: 684-688.
10. Feigh M, Henriksen K, Andreassen KV, Hansen C, Henriksen JE, Beck-Nielsen H, et al,. (2011). A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats. Diabetes Obes Metab 13: 911-920.
11. Feigh M, Nielsen RH, Hansen C, Henriksen K, Christiansen C, Karsdal MA, (2012). Oral salmon calcitonin improves fasting and postprandial glycemic control in lean healthy rats. Horm Metab Res 44: 130-134.
12. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG, (2002). The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res 34: 504-508.
13. Gedulin BR, Rink TJ, Young AA, (1997). Dose-response for glucagonostatic effect of amylin in rats. Metabolism 46: 67-70.
14. Granberry MC, Hawkins JB, Franks AM, (2007). Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure. Am J Health Syst Pharm 64: 931-936.
15. Hay DL, Christopoulos G, Christopoulos A, Sexton PM, (2004). Amylin receptors: molecular composition and pharmacology. Biochem Soc Trans 32: 865-867.
16. Hay DL, Christopoulos G, Christopoulos A, Poyner DR, Sexton PM, (2005). Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. Mol Pharmacol 67: 1655-1665.
17. Hollander P, Ratner R, Fineman M, Strobel S, Shen L, Maggs D, et al,. (2003a). Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab 5: 408-414.
18. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, et al,. (2003b). Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 26: 784-790.
19. Holst JJ, Deacon CF, Vilsboll T, Krarup T, Madsbad S, (2008). Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med 14: 161-168.
20. Kahn SE, (2003). The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46: 3-19.
21. Kahn SE, Zraika S, Utzschneider KM, Hull RL, (2009). The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 52: 1003-1012.
22. Kawamori D, Kulkarni RN, (2009). Insulin modulation of glucagon secretion: the role of insulin and other factors in the regulation of glucagon secretion. Islets 1: 276-279.
23. Kiec-Klimczak ME, Pach DM, Pogwizd ME, Hubalewska-Dydejczyk AB, (2011). Incretins yesterday, pleiotropic gastrointestinal hormones today:glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Recent Pat Endocr Metab Immune Drug Discov 5: 176-182.
24. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
25. Krentz AJ, Patel MB, Bailey CJ, (2008). New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs 68: 2131-2162.
26. Kruger DF, Boucher JL, Banerji MA, (2011). Utilizing current diagnostic criteria and treatment algorithms for managing type 2 diabetes mellitus. Postgrad Med 123: 54-62.
27. Larsen PJ, Wulff EM, Gotfredsen CF, Brand CL, Sturis J, Vrang N, et al,. (2008). Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats. Diabetes Obes Metab 10: 301-311.
28. Lutz TA, Senn M, Althaus J, Del PE, Ehrensperger F, Scharrer E, (1998). Lesion of the area postrema/nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats. Peptides 19: 309-317.
29. Lutz TA, Tschudy S, Rushing PA, Scharrer E, (2000). Amylin receptors mediate the anorectic action of salmon calcitonin (sCT). Peptides 21: 233-238.
30. Mack CM, Smith PA, Athanacio JR, Xu K, Wilson JK, Reynolds JM, et al,. (2011). Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide. Diabetes Obes Metab 13: 1105-1113.
31. Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, et al,. (2004). Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev 20: 55-60.
32. Malkov D, Angelo R, Wang HZ, Flanders E, Tang H, Gomez-Orellana I, (2005). Oral delivery of insulin with the eligen technology: mechanistic studies. Curr Drug Deliv 2: 191-197.
33. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
34. Paulsen SJ, Vrang N, Larsen LK, Larsen PJ, Jelsing J, (2010). Stereological assessment of pancreatic beta-cell mass development in male Zucker Diabetic Fatty (ZDF) rats: correlation with pancreatic beta-cell function. J Anat 217: 624-630.
35. Potes CS, Turek VF, Cole RL, Vu C, Roland BL, Roth JD, et al,. (2010). Noradrenergic neurons of the area postrema mediate amylin's hypophagic action. Am J Physiol Regul Integr Comp Physiol 299: R623-R631.
36. Purdue BW, Tilakaratne N, Sexton PM, (2002). Molecular pharmacology of the calcitonin receptor. Receptors Channels 8: 243-255.
37. Reidelberger RD, Kelsey L, Heimann D, (2002). Effects of amylin-related peptides on food intake, meal patterns, and gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 282: R1395-R1404.
38. Roth JD, Hughes H, Kendall E, Baron AD, Anderson CM, (2006). Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology 147: 5855-5864.
39. Roth JD, Trevaskis JL, Wilson J, Lei C, Athanacio J, Mack C, et al,. (2008). Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats. Int J Obes (Lond) 32: 1201-1210.
40. Rowe R, Cowx M, Poole C, Mcewan P, Morgan C, Walker M, (2005). The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss. Curr Med Res Opin 21: 1885-1890.
41. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, (2006). Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368: 1660-1672.
42. Steinert RE, Poller B, Castelli MC, Friedman K, Huber AR, Drewe J, et al,. (2009). Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. Clin Pharmacol Ther 86: 644-650.
43. Steinert RE, Poller B, Castelli MC, Drewe J, Beglinger C, (2010). Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. Am J Clin Nutr 92: 810-817.
44. Tilakaratne N, Christopoulos G, Zumpe ET, Foord SM, Sexton PM, (2000). Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. J Pharmacol Exp Ther 294: 61-72.
45. Tokuyama Y, Sturis J, Depaoli AM, Takeda J, Stoffel M, Tang J, et al,. (1995). Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes 44: 1447-1457.
46. Topp BG, Atkinson LL, Finegood DT, (2007). Dynamics of insulin sensitivity, -cell function, and -cell mass during the development of diabetes in fa/fa rats. Am J Physiol Endocrinol Metab 293: E1730-E1735.
47. Trevaskis JL, Coffey T, Cole R, Lei C, Wittmer C, Walsh B, et al,. (2008). Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology 149: 5679-5687.
48. Trevaskis JL, Turek VF, Wittmer C, Griffin PS, Wilson JK, Reynolds JM, et al,. (2010). Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats. Endocrinology 151: 5657-5668.
49. Turek VF, Trevaskis JL, Levin BE, Dunn-Meynell AA, Irani B, Gu G, et al,. (2010). Mechanisms of amylin/leptin synergy in rodent models. Endocrinology 151: 143-152.
50. Wajchenberg BL, (2007). beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 28: 187-218.
51. Young AA, Gedulin B, Vine W, Percy A, Rink TJ, (1995). Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 38: 642-648.